SC
AMPH icon

Schubert & Co’s Amphastar Pharmaceuticals AMPH Stock Holding History

Schubert & Co’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3
Closed -$113 – 111
2023
Q1 		$113 Buy
3
+2
+200% +$66 ﹤0.01% 1592
2022
Q4 		$28 Hold
1
– – ﹤0.01% 1622
2022
Q3 		$0 Buy
+1
New +$33 ﹤0.01% 1365

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Schubert & Co's AMPH Position: Q2 2023 in Review

Schubert & Co sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2023, closing a stake of 3 shares — an estimated $113 sold.

Schubert & Co first reported a position in AMPH in Q3 2022 and held it in 3 quarters. The position peaked at $113 in Q1 2023. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2023.

  • Schubert & Co reported no remaining Amphastar Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 3 Amphastar Pharmaceuticals shares in Q2 2023, an estimated $113.
  • Schubert & Co first reported a position in Amphastar Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Schubert & Co's Amphastar Pharmaceuticals position peaked at $113 in Q1 2023.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.